Pibrentasvir

Cas：1353900-92-1 (free)

Product Information：

Pibrentasvir, also known as ABT-530, is a protease inhibitor potentially for the treatment of HCV infection.

Chemical Formula: C57H65F5N10O8

Exact Mass: 1112.4907

Molecular Weight: 1113.2

Elemental Analysis: C, 61.50; H, 5.89; F, 8.53; N, 12.58; O, 11.50

Synonym: 

ABT-530

ABT530

ABT 530

A-1325912

A 1325912

A1325912

A-1325912.0

A 1325912.0

A1325912.0

Chemical Name: 

dimethyl((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate

InChi Key: 

VJYSBPDEJWLKKJ-NLIMODCCSA-N

InChi Code: InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

Smiles Code:

FC1=CC=C(C=C1)C2CCN(CC2)C3=C(C=C(C=C3F)N4[C@H](CC[C@@H]4C5=C(F)C=C6NC([C@@H]7CCCN7C([C@@H](NC(OC)=O)[C@H](OC)C)=O)=NC6=C5)C8=C(C=C9C(N=C([C@@H]%10CCCN%10C([C@@H](NC(OC)=O)[C@H](OC)C)=O)N9)=C8)F)F

Technical Data：

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

References：

1. Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol. 2019 Jan;14:89-110. doi: 10.2217/fmb-2018-0233. Epub 2018 Nov 30. Review. PubMed PMID: 30499343.

2. Clinical Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533768/ PubMed PMID: 30462453.

3. Pharmacoeconomic Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533682/ PubMed PMID: 30462452.

4. CADTH Canadian Drug Expert Committee Recommendation: Glecaprevir / Pibrentasvir (Maviret — Abbvie Corporation): Indication: Chronic hepatitis C virus infection [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533338/ PubMed PMID: 30457786.

5. Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr. 2018 Oct;41(5):169-170. doi: 10.18773/austprescr.2018.050. Epub 2018 Aug 2. Review. PubMed PMID: 30410216; PubMed Central PMCID: PMC6202291.

Products are for research use only. Not for human use.